Published in Nature on April 04, 2002
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
The expanding universe of p53 targets. Nat Rev Cancer (2009) 3.49
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature (2010) 3.37
TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell (2009) 3.15
p53 and E2f: partners in life and death. Nat Rev Cancer (2009) 3.06
The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol (2003) 3.00
Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol (2004) 2.75
Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res (2008) 2.67
The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol (2011) 2.13
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ (2011) 1.94
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev (2013) 1.88
Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol (2002) 1.83
The p53 family and programmed cell death. Oncogene (2008) 1.81
TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab (2012) 1.77
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 1.73
The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. EMBO Rep (2009) 1.69
IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature (2014) 1.66
Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63
Splitting p63. Am J Hum Genet (2002) 1.62
TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol (2013) 1.61
Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene (2008) 1.57
DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol (2004) 1.56
Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. EMBO J (2009) 1.54
New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J (2006) 1.50
p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A (2006) 1.48
Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A (2003) 1.47
The p53 Family Coordinates Wnt and Nodal Inputs in Mesendodermal Differentiation of Embryonic Stem Cells. Cell Stem Cell (2016) 1.46
CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes Dev (2007) 1.45
p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet (2009) 1.41
SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J (2002) 1.39
Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res (2008) 1.37
p53 Isoforms: An Intracellular Microprocessor? Genes Cancer (2011) 1.37
p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol (2003) 1.36
p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer (2013) 1.34
A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol (2008) 1.34
Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest (2012) 1.29
Direct targets of the TRP63 transcription factor revealed by a combination of gene expression profiling and reverse engineering. Genome Res (2008) 1.29
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest (2007) 1.27
Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ (2011) 1.26
p53 Family: Role of Protein Isoforms in Human Cancer. J Nucleic Acids (2011) 1.26
Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol (2009) 1.25
The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol (2006) 1.24
Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med (2004) 1.24
Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle (2012) 1.23
MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol (2006) 1.23
Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci U S A (2005) 1.21
Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res (2009) 1.19
Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63. Nucleic Acids Res (2006) 1.13
Transcriptional profiling in C. elegans suggests DNA damage dependent apoptosis as an ancient function of the p53 family. BMC Genomics (2008) 1.11
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev (2010) 1.11
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer (2010) 1.11
p63 and p73 coordinate p53 function to determine the balance between survival, cell death, and senescence in adult neural precursor cells. Cell Death Differ (2014) 1.11
p53-independent apoptosis limits DNA damage-induced aneuploidy. Genetics (2009) 1.09
Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem (2009) 1.09
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proc Natl Acad Sci U S A (2011) 1.08
Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J (2007) 1.07
The C-terminus of p63 contains multiple regulatory elements with different functions. Cell Death Dis (2010) 1.07
hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol (2009) 1.06
Measles virus V protein inhibits p53 family member p73. J Virol (2006) 1.06
Dual roles of Drosophila p53 in cell death and cell differentiation. Cell Death Differ (2009) 1.05
ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle (2008) 1.05
Multiple stress signals induce p73beta accumulation. Neoplasia (2004) 1.05
p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology (2013) 1.05
E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol (2009) 1.04
DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol (2005) 1.04
Restriction of Src activity by Cullin-5. Curr Biol (2009) 1.04
Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res (2008) 1.03
Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ (2011) 1.03
Smoking, p53 mutation, and lung cancer. Mol Cancer Res (2014) 1.03
MicroRNAs and p63 in epithelial stemness. Cell Death Differ (2014) 1.03
ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization. Cell Death Differ (2011) 1.02
Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC Cancer (2013) 1.02
Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet (2010) 1.01
Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch (2003) 1.01
p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab (2005) 1.01
Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity. Cell Death Differ (2013) 1.00
Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation. Mol Cell Biol (2004) 1.00
Scission of the p53-MDM2 Loop by Ribosomal Proteins. Genes Cancer (2012) 1.00
Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep (2012) 0.99
Normal p53 function in primary cells deficient for Siah genes. Mol Cell Biol (2002) 0.99
DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B (2007) 0.99
DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res (2011) 0.98
p63 the guardian of human reproduction. Cell Cycle (2012) 0.98
Cell cycle regulation in the developing lens. Semin Cell Dev Biol (2006) 0.97
UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle (2011) 0.97
Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci U S A (2012) 0.96
Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest (2012) 0.96
p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage. J Biol Chem (2013) 0.96
Tumor suppression by p53: making cells senescent. Histol Histopathol (2010) 0.96
Stimulus-specific transcriptional regulation within the p53 network. Cell Cycle (2007) 0.95
Analysis of the oligomeric state and transactivation potential of TAp73α. Cell Death Differ (2013) 0.94
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther (2010) 0.94
Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. Cell Cycle (2011) 0.94
The p53 isoforms are differentially modified by Mdm2. Cell Cycle (2012) 0.94
Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem (2007) 0.94
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell (2010) 12.27
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 6.01
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell (2006) 4.51
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 3.57
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 3.54
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell (2009) 3.15
Cancer modeling in the modern era: progress and challenges. Cell (2002) 3.12
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature (2002) 3.05
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev (2013) 2.90
Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol (2011) 2.72
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A (2002) 2.24
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell (2003) 2.23
Cell type-specific effects of Rb deletion in the murine retina. Genes Dev (2004) 2.18
Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc Natl Acad Sci U S A (2007) 2.18
The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat Immunol (2003) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Selective ablation of alphav integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development (2004) 2.14
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell (2013) 2.05
Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell (2012) 2.04
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A (2010) 1.95
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A (2005) 1.91
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell (2004) 1.86
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem (2005) 1.85
Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem (2002) 1.82
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev (2007) 1.81
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell (2003) 1.78
TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab (2012) 1.77
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76